✦ LIBER ✦

Tamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy

✍ Scribed by V. C. Jordan; J. I. MacGregor; D. A. Tonetti

Publisher: Springer-Verlag
Year: 1997
Tongue: English
Weight: 651 KB
Volume: 7
Category: Article
ISSN: 0937-941X
DOI: 10.1007/bf01674814

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of switching to exeme

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to

Vaginal cytology as an aid to hormone th

Vaginal cytology as an aid to hormone therapy in postmenopausal cancer of the breast

✍ Basil A. Stoll 📂 Article 📅 1967 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br

The addition of hormone therapy to tamox

The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer

✍ Cynthia R. Osborne; Anita Duncan; Scot Sedlacek; Devchand Paul; Frankie Holmes; 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 170 KB

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

Systemic therapy of inflammatory breast

Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies : The French experience

✍ Patrice Viens; Carole Tarpin; Henri Roche; François Bertucci 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 1 views

## Abstract ## BACKGROUND: Aggressiveness of inflammatory breast cancer (IBC) is related to its metastatic potential. The introduction of primary chemotherapy in the multimodality treatment has dramatically changed the prognosis. However, survival remains poor. Since 1995, innovative systemic ther